{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:51:45Z","timestamp":1791215505357,"version":"4.1.0"},"reference-count":27,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"abstract":"\n Importance<\/jats:title>\n The COVID-19 pandemic disproportionately affected patients with autoimmune and rheumatic diseases. Understanding whether certain medications affect the response to a SARS-CoV-2 supplemental dose vaccination is critical for counseling and treating patients receiving targeted immunomodulatory medications. The effect of holding these medications around the time of COVID-19 vaccination on immunogenicity and rheumatic disease outcomes has not been well studied.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess whether temporarily holding biologic or targeted synthetic disease-modifying antirheumatic drug therapy improves humoral immunogenicity following COVID-19 supplemental dose vaccination in patients with inflammatory arthritis as well as evaluate whether such interruption worsened disease activity.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n The COVID-19 Vaccine Response (COVER) trial was a multicenter randomized clinical pragmatic trial conducted from November 2021 to May 2024 of patients with rheumatoid arthritis, psoriatic arthritis, and axial spondylarthritis who were receiving care in the Excellence Network in Rheumatology to Innovate Care and High-Impact Research (ENRICH) practice-based network. Data were analyzed from June 2024 to April 2026.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Patients had received a primary messenger RNA COVID-19 vaccine series and were receiving stable immunomodulatory therapy with anti\u2013tumor necrosis factor, anti\u2013interleukin-17, abatacept, and a Janus kinase inhibitor (JAKi). Patients were randomized to continue or hold therapy for 2 weeks following their next COVID-19 supplemental dose administration.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was change in immunoglobulin G levels against the SARS-CoV-2 spike protein from baseline to 6-week follow-up, expressed as the geometric mean fold rise (GMFR). The primary analysis followed an intention-to-treat (ITT) principle, with missing outcomes addressed through multiple imputations. A per-protocol sensitivity analysis was also conducted. Secondary outcomes included disease flares and vaccine-related adverse events.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 840 randomized participants (continue group: 319 female individuals [76%]; mean [SD] age, 60.0 [12.9] years; hold group: 336 female individuals [80%]; mean [SD] age, 59.1 [12.9] years), substantial increases in SARS-CoV-2 spike immunoglobulin G antibody levels were observed across all groups from baseline to the postdose visit. In the primary ITT analysis, the GMFR ratio (hold\/continue) was 0.96 (95% CI, 0.36-2.56), indicating no significant difference in humoral immunogenicity between arms. Results were consistent across drug subgroups and drug half-life categories. Holding therapy significantly increased disease flare risk (odds ratio, 2.27; 95% CI, 1.41-3.65), which was most pronounced among those who used JAKi; the Outcome Measures in Rheumatology RA Flare Questionnaire corroborated this perivaccination signal (54 of 256 [21.1%] vs 23 of 253 [9.1%] with \u226510-point worsening; risk difference, 12.0%; 95% CI, 5.9%-18.1%), with full recovery in both arms by 6-week follow-up. Adverse events were comparable between medication arms and were more frequent in the hold group.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This randomized clinical trial found that, among patients with inflammatory arthritis, holding select biologic or JAKi therapies for 2 weeks at the time of supplemental COVID-19 vaccine dose did not significantly enhance humoral immunogenicity and was associated with transient but clinically meaningful disease flare. Routine interruption of these therapies at the time of COVID-19 dose administration is likely not warranted.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT05080218<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamainternmed.2026.4894","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:00:37Z","timestamp":1791212437000},"source":"Crossref","is-referenced-by-count":0,"title":["Temporary Cessation of DMARD Therapy and COVID-19 Supplemental Dose Vaccine Immunogenicity in Patients With Inflammatory Arthritis"],"prefix":"10.1001","author":[{"given":"Jeffrey R.","family":"Curtis","sequence":"first","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Mudano","sequence":"additional","affiliation":[{"name":"Foundation for Advancement of Science, Technology and Education in Rheumatology, Hoover, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Cutter","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted R.","family":"Mikuls","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center, Omaha"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"George","sequence":"additional","affiliation":[{"name":"Divisions of Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey M.","family":"Thiele","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center, Omaha"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Law","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center, Omaha"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly Y.","family":"Chun","sequence":"additional","affiliation":[{"name":"Esoterix Labcorp, Calabasas, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Bastidas","sequence":"additional","affiliation":[{"name":"Esoterix Labcorp, Calabasas, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Zikry","sequence":"additional","affiliation":[{"name":"Esoterix Labcorp, Calabasas, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep K.","family":"Sodhi","sequence":"additional","affiliation":[{"name":"Illumination Health, Hoover, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayashree","family":"Sinha","sequence":"additional","affiliation":[{"name":"Clovis, New Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Tesser","sequence":"additional","affiliation":[{"name":"Arizona Arthritis and Rheumatology Research, The University of Arizona College of Medicine, Phoenix"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naiara","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Integrative Rheumatology of South Texas, Harlingen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[{"name":"Oregon Health Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"issue":"9","key":"ioi260058r1","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.cmi.2022.05.005","article-title":"Immunocompromised patients have been neglected in COVID-19 trials: a call for action.","volume":"28","author":"Tr\u00f8seid","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"SI","key":"ioi260058r2","doi-asserted-by":"publisher","first-page":"SI59","DOI":"10.1093\/rheumatology\/keaa897","article-title":"Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark.","volume":"60","author":"Cordtz","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"ioi260058r3","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/art.41619","article-title":"COVID-19 outcomes in patients with systemic autoimmune rheumatic diseases compared to the general population: a US multicenter, comparative cohort study.","volume":"73","author":"D\u2019Silva","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"ioi260058r4","doi-asserted-by":"publisher","first-page":"e274","DOI":"10.1016\/S2665-9913(21)00401-X","article-title":"Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study.","volume":"4","author":"Topless","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"7821","key":"ioi260058r5","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY.","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"issue":"1","key":"ioi260058r6","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/art.42372","article-title":"American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 5.","volume":"75","author":"Curtis","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"ioi260058r7","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1093\/rheumatology\/keab223","article-title":"COVID-19 vaccination and antirheumatic therapy.","volume":"60","author":"Arnold","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"ioi260058r8","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.","volume":"80","author":"Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"ioi260058r9","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3390\/vaccines12030274","article-title":"Impact of immunomodulatory therapy on COVID-19 vaccine response in patients with autoimmune inflammatory rheumatic diseases.","volume":"12","author":"Yap","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"ioi260058r10","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1016\/S2665-9913(23)00298-9","article-title":"Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial.","volume":"6","author":"Abhishek","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"ioi260058r11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41541-024-00805-3","article-title":"Beneficial effect of temporary methotrexate interruption on B and T cell responses upon SARS-CoV-2 vaccination in patients with rheumatoid arthritis or psoriatic arthritis.","volume":"9","author":"Mart\u00ednez-Fleta","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"6","key":"ioi260058r12","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1136\/annrheumdis-2018-213222","article-title":"Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial.","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"ioi260058r13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/art.42318","article-title":"A multicenter, prospective, randomized, parallel-group trial on the effects of temporary methotrexate discontinuation for one week versus two weeks on seasonal influenza vaccination in patients with rheumatoid arthritis.","volume":"75","author":"Park","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"50","key":"ioi260058r14","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.15585\/mmwr.mm6950e2","article-title":"The Advisory Committee on Immunization Practices\u2019 interim recommendation for use of Pfizer-BioNTech COVID-19 Vaccine\u2014United States, December 2020.","volume":"69","author":"Oliver","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"ioi260058r15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both.","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"ioi260058r16","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70067","article-title":"Generating real-world evidence from the excellence network in rheumatology.","volume":"33","author":"Beukelman","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"ioi260058r18","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.3899\/jrheum.161145","article-title":"Content and construct validity, reliability, and responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 workshop report.","volume":"44","author":"Bartlett","year":"2017","journal-title":"J Rheumatol"},{"key":"ioi260058r19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jclinepi.2015.08.038","article-title":"PROMIS measures of pain, fatigue, negative affect, physical function, and social function demonstrated clinical validity across a range of chronic conditions.","volume":"73","author":"Cook","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"ioi260058r22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s12891-016-1082-z","article-title":"Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept.","volume":"17","author":"Alten","year":"2016","journal-title":"BMC Musculoskelet Disord"},{"issue":"10","key":"ioi260058r23","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1136\/annrheumdis-2021-220597","article-title":"Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease.","volume":"80","author":"Haberman","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"ioi260058r24","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/S2213-2600(22)00186-2","article-title":"Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial.","volume":"10","author":"Abhishek","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"11","key":"ioi260058r25","doi-asserted-by":"publisher","first-page":"e755","DOI":"10.1016\/S2665-9913(22)00228-4","article-title":"Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised controlled trials.","volume":"4","author":"Skaria","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"ioi260058r26","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals.","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"issue":"8","key":"ioi260058r27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41577-020-0389-z","article-title":"Pre-existing immunity to SARS-CoV-2: the knowns and unknowns.","volume":"20","author":"Sette","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"ioi260058r17","unstructured":"REDCap Cloud. Unified data science platform. Accessed May 1, 2024. https:\/\/www.redcapcloud.com\/"},{"key":"ioi260058r20","unstructured":"US Centers for Disease Control and Prevention. Vaccine Adverse Event Reporting System (VAERS). Accessed March 31, 2026. http:\/\/vaers.hhs.gov"},{"key":"ioi260058r21","unstructured":"LabCorp. SARS-CoV-2 semi-quantitative total antibody, spike. Accessed March 31, 2026. https:\/\/www.labcorp.com\/tests\/164090\/sars-cov-2-semi-quantitative-total-antibody-spike."}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2854542\/jamainternal_curtis_2026_oi_260058_1789768862.38818.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:00:38Z","timestamp":1791212438000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2854542"}},"subtitle":["The COVER Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":27,"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2026.4894","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,5]]}}}